Streetbeat News

Products Services

AMC

Taylor Swift's Eras Tour Film is expected to maintain its No. 1 spot after earning $10.4M on Friday. The film is likely being shown in AMC theaters.

Portfolio Pulse from Charles Gross

October 21, 2023 | 8:01 pm

HARP

Harpoon Therapeutics, Inc. (NASDAQ:HARP) announced updated interim data from its Phase 1/2 clinical trial of T cell engager HPN328, showing a confirmed response rate of 35% across all tumor types and patient cohorts treated with a 1 mg priming dose. The trial is nearing completion and the company is on track to select Phase 2 doses by the end of 2023.

Portfolio Pulse from Charles Gross

October 21, 2023 | 6:09 pm

AZN

AstraZeneca announced that its drug TAGRISSO, when combined with chemotherapy, reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases. This is based on the results from a prespecified exploratory analysis of the FLAURA2 Phase III trial. The results were presented at the European Society for Medical Oncology Congress in Madrid, Spain.

Portfolio Pulse from Charles Gross

October 21, 2023 | 4:59 pm

TSLA

Tesla Inc's Cybertruck, set to launch on Nov. 30, has been tested for its bulletproof claim. New images and a video show the Cybertruck's doors dented but not compromised after being shot multiple times with a Thompson submachine gun. Tesla CEO Elon Musk confirmed the extreme durability test, stating that no bullets penetrated into the passenger compartment.

Portfolio Pulse from Benzinga EV Insights

October 21, 2023 | 1:46 pm

AZN

AstraZeneca announced positive results from the interim analysis of the MATTERHORN Phase III trial. The trial showed that AstraZeneca's IMFINZI in combination with standard-of-care FLOT neoadjuvant chemotherapy demonstrated a significant improvement in the pathologic complete response for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers.

Portfolio Pulse from Charles Gross

October 21, 2023 | 1:43 pm

ORIC

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced initial data from the ongoing ORIC-114 Phase 1 dose escalation trial for patients with EGFR or HER2 exon 20 mutated non-small cell lung cancer. The data shows CNS activity at multiple dose levels, systemic responses in heavily pre-treated NSCLC patients, and a favorable safety profile. The company believes this demonstrates a potential best-in-class profile for ORIC-114.

Portfolio Pulse from Charles Gross

October 21, 2023 | 1:28 pm

IMCR

Immunocore Holdings plc (NASDAQ:IMCR) announced that the three-year overall survival data from the KIMMTRAK Phase 3 trial in previously untreated HLA-A*02:01 positive patients with metastatic uveal melanoma has been published in The New England Journal of Medicine. The data was also presented at the European Society for Medical Oncology (ESMO) Congress 2023. KIMMTRAK demonstrated long-term survival benefit in these patients.

Portfolio Pulse from Charles Gross

October 21, 2023 | 1:25 pm

REGN

Regeneron Pharmaceuticals announced key secondary endpoints for Libtayo as a neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma. The results from a Phase 2 trial showed 89% estimated event-free survival at one year among patients who received Libtayo prior to surgery. No disease recurrence was observed among the 51% of patients who experienced a pathologic complete response.

Portfolio Pulse from Charles Gross

October 21, 2023 | 1:21 pm

EPIX

ESSA Pharma Inc. (NASDAQ:EPIX) has announced updated dose escalation data from its Phase 1/2 study evaluating masofaniten in combination with enzalutamide for the treatment of prostate cancer. The data, presented at the ESMO 2023 Congress, shows that the combination is well tolerated and results in significant reductions in prostate-specific antigen (PSA) in patients with metastatic castration-resistant prostate cancer (mCRPC). Across all cohorts, 69% of patients achieved PSA90, 63% achieved PSA90 in less than 90 days, and 56% achieved PSA <0.2mg/mL.

Portfolio Pulse from Charles Gross

October 21, 2023 | 1:17 pm

NIO

Chinese EV maker Nio Inc has opened its F2 manufacturing center at Neopark in Hefei, China to the public. The center is a fully digitalized smart factory covering the entire value chain. Nio offers over 3.5 million different possible configurations across eight different models and delivers the vehicle within 21 days of order confirmation. The joining process at the center is fully automated and is enabled 756 robots.

Portfolio Pulse from Anan Ashraf

October 21, 2023 | 10:35 am